hat
MMAE se yon sentetik antineoplastik ajan, ki pa ka itilize kòm yon dwòg tèt li akòz toksisite segondè li yo; olye, li konjige yon mAb pou fòme ADC yo. Malgre ke anba envestigasyon pou dè dekad, ADCs te resevwa renouvle atansyon ak avènement de pwogrè siyifikatif nan jeni nouvo linker ak teknoloji konjugasyon ansanm ak trè dwòg cytotoxik trè ki pisan. Ki pi souvan itilize toksin yo pou ADC nan devlopman nan klinik yo maytansine, calicheamicin, ak dérivés auristatin.
eng
MMAE is a synthetic antineoplastic agent, which cannot be used as a drug itself due to its high toxicity; instead, it is conjugate to a mAb to form ADCs. Although under investigation for decades, ADCs have received renewed attention with the advent of significant advances in engineering new linker and conjugation technologies together with highly potent cytotoxic drugs. The most commonly used toxins for ADCs in clinical development are maytansine,calicheamicin,and auristatin derivatives.